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Domestically produced, high potency cannabis (often referred to as “skunk” in mainstream British media) has become increasingly widespread in the UK.  This paper considers whether this trend reflects increased awareness of and desire for medical marijuana. Determining whether cannabis is a drug or a medicine depends on its objective physiological effects, which may vary from one individual to another, as well as how and why those effects are experienced. Medicinal and mind-altering effects of cannabis are not easily separable for many cannabis users. The medicinal use of cannabis in Britain has waxed and waned since the early 19th century. Currently the UK is on the cutting edge of the development of cannabis-based pharmaceuticals, but criminalizes people who choose to self-medicate with herbal cannabis. We are living in time of political, social and economic uncertainty, which threatens the stability of national healthcare systems. The broad ranging effects of cannabis on the human body and mind, combined with its relatively easy cultivation, make it a sustainable and effective alternative medicine. Research is needed, especially on the experiences of people who use cannabis to benefit, enrich and even prolong their lives.
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Introduction
The word skunk has many different meanings in the English language and is what linguists call a polysemous term.  With regard to cannabis alone, skunk refers to at least three distinct phenomena.  From an ethnobotanical perspective skunk is the name of a strain of cannabis that is particularly fragrant, especially when grown with care and proper nourishment.  In mainstream UK media, the term skunk can refer to any strain of cannabis that has been grown with methods that maximize the amount of the plant’s active compounds (known collectively as cannabinoids), delta-9-tetrahydrocannabinol (THC), in particular.  And among students and recent graduates of my university, the term skunk refers to cannabis that has been adulterated to look like it is highly potent.  Thus, when people say they do or do not like skunk, or when skunk is associated with mental health problems we cannot draw general conclusions about cannabis without specifying the particular form in question (i.e. a specific strain of cannabis with a unique profile of cannabinoids, any variety of high potency cannabis or adulterated cannabis).

The multiple meanings of skunk in the UK have led to confusion about and fear of high potency cannabis, with a number of unfortunate side effects.  Some people may have unpleasant experiences when they encounter unexpectedly strong forms of the plant and it is not clear whether this is an effect of the actual cannabis or of cannabis propaganda (Sumnall & Bellis 2007).  Others, who are looking for extreme highs (but are otherwise inexperienced with cannabis) may expose themselves unknowingly to toxic contaminants, especially cannabis that has been sprayed with silica or glass crystals (Klein & Doctors 2006).  Professional adults (including politicians) hypocritically defend their own use of cannabis and condemn other people’s use by arguing that the skunk of today is a different drug than the cannabis of their youth (Stevens 2007). But from my perspective as a medical anthropologist, most unfortunate is uniform demonization of all highly potent forms of cannabis, including medicinal varieties.

Is Cannabis a Drug or a Medicine?
The terms drug and medicine are also polysemous, especially when used in relation to cannabis.  In pharmacology drugs are substances that contain small molecules, which have physiological effects on biological systems (Brody 1998).  In the social sciences the term drugs usually refers to illicit substances that are consumed for illicit (or at best hedonistic) purposes, while in medicine drugs (especially commercially produced, professionally prescribed pharmaceuticals) are synonymous with medicines.  Anthropological research suggests that medicines can be defined as non-nutritive substances that restore patho-physiological disease states.  But there is considerable overlap among medicines, foods and poisons in most ethnomedical systems (Etkin & Ross 1982; Hugh-Jones 1993).  Depending on one’s perspective, cannabis can be illustrative of all of these definitions.  This is a result of the way the human body produces and uses cannabinoids and also the ways that cannabis is experienced subjectively by a variety of genetically and culturally diverse individuals. 

Like most mammals, humans produce cannabis-like compounds known as endocannabinoids.  Endocannabinoids control basic metabolic processes within cells, intercellular communication and the modulation and coordination of tissues, organs and body systems (Melamede 2005). Both endocannabinoids and phytocannabinoids (from cannabis plants) exert their effects by interacting with at least two different types of cannabinoid receptors (CB1 and CB2) that are present on various cells throughout the human body.  CB1 receptors are found in high concentrations on cells in the spinal-cord regions associated with pain, as well as in many parts of the brain (such as the basal ganglia, cerebellum and hippocampus). However, there are minimal CB1 receptors in the brainstem, which likely accounts for the lack of acute cannabis induced fatalities.  CB2 receptors are expressed primarily by white blood cells (Baker et al. 2003) but are also found in most other organ systems.  

Russo (2004) has theorized that a clinical endocannabinoid deficiency may account for migraine, fibromyalgia, irritable bowel syndrome and other disorders characterized by increased sensitivity to pain.  Chronically low levels of endocannabinoids are also implicated in anxiety and depression (Hill & Gorzalka 2005; Viveros et al. 2007). Variation in endocannabinoid activity implies that while some individuals would be overly sensitive to increases in cannabinoid levels resulting from the consumption of cannabis, others would benefit from increased cannabinoid levels (Melamede 2005).

Although generations of selective breeding have produced countless strains of cannabis, each with a unique profile of chemical compounds, most types contain around 60 different cannabinoids (Ben Amar 2006).  THC is the most well studied cannabinoid and both psychoactive and medical effects of cannabis are generally attributed to it.  However, THC alone does not account for the plant’s ability to alter the consciousness of the consumer or to heal various signs and symptoms of disease.  This helps to explain why medical research on cannabis and cannabinoids is so equivocal (Russo & McPartland 2003). Strains of cannabis with varying cannabinoid profiles may have different physiological effects on different individuals.  Determining whether cannabis is a medicine that can be used to heal or a drug that can potentially cause harm depends on the strain, as well as the person in question.  This is complicated further by the apparent biphasic actions of many cannabinoids, which may produce one effect at low doses and the opposite effect at high doses (Hill et al. 2006; Melamede 2005; Viveros et al. 2007).  

Determining whether cannabis is a drug or a medicine not only depends on its objective physiological effects, but also on how and why those effects are experienced. The effects of cannabis on consciousness can range from subtle shifts in sensitivity to one's environment, cognitive clarity and/or reduced anxiety (Lenza 2007) to feelings of dizziness, confusion and disorientation (Becker 1953).  Qualitative studies of cannabis users suggest that the experience of being “high” is socially learned (Becker 1953; Lenza 2007), however there appears to be individual variation about what exactly constitutes a “high” (Coomber et al. 2003). In a study of the use of cannabis to manage problematic drinking, informants reported taking low doses of cannabis to achieve a state of being “high” that facilitated writing, studying and creative activities.  This “high” was contrasted with over-consumption of cannabis (referred to as being “wasted,” “baked” or “really stoned”), which was associated with cognitive and physical impairment (Lenza 2007).  In another qualitative study of medical marijuana users the majority of the 33 participants reported that they did not need to get “high” to get therapeutic effects from cannabis. Nevertheless, some participants reported that mood enhancement, feelings of well being and/or creativity (derived from the psychoactive properties of cannabis) were some of the therapeutic outcomes of use (Coomber et al. 2003). It seems that experiences of medicinal and mind-altering effects of cannabis are not easily separable for many cannabis users (Chapkis 2007; Coomber et al. 2003; Lenza 2007).  Moreover, cannabis may also act as a preventative medicine for minor chronic conditions (e.g. aches and pains or mild depression) that is not necessarily recognized as such by regular recreational users.

Medicinal Cannabis in Britain
The medical use of cannabis was introduced to Britain from India in the 19th Century.  Sir William O'Shaughnessy's work was most influential and included contemporary and classical ethnobotanical uses of various types of cannabis, as well as the findings of a series of human clinical trials. Throughout the 19th Century a series of medical practitioners from both India and Great Britain noted success in extending the use of cannabis as a medicine for a seemingly endless list of conditions (Russo 2005).  However, cannabis remained under intense scrutiny by colonial officials, due to its popularity with disenfranchised members of Indian society and the influence of a small but vocal group of missionaries who helped push the ideology of the Temperance movement through the House of Commons (Mills 2005). The Indian Hemp Drugs Commission (IHDC) was appointed in 1893 and took evidence from over 1000 British and Indian people about the effects of cannabis on mental and physical health.  Despite the fact that Temperance advocates actively recruited missionaries known to have negative views about cannabis to give evidence to the Commission (Mills 2005) and that Unani and folk medical practitioners were completely excluded (Basu 2000) it was concluded that moderate use of cannabis had no negative physical, mental or moral effects.  While it was acknowledged that excessive use tended to 'weaken the constitution' and ‘intensify mental instability,’ the Commission's report also emphasized that moderate use of Indian hemp was the norm and that excessive use was rare (Kendell 2008). 

Nevertheless, by the beginning of the 20th Century the use of cannabis medicines began to decline in the UK due to continuing political controversy and quality control problems with cannabis imported from India (Russo 2005).  Between 1920 and 1960, interest in and knowledge of the therapeutic properties of cannabis fell into obscurity in the UK. This related to the growing international prohibitionist movement and to cannabis’ inability to compete with opium (Taylor 2008). Cannabis became subject to international legislation unexpectedly in 1925 at the Second Opium Conference of the League of Nations.  At this meeting an Egyptian delegate asked for cannabis to be included on the list of narcotics to be regulated by the conference even though it was not on the agenda and delegates were not briefed about the drug.  While British/Indian delegates were among the few who expressed doubt about the inclusion of cannabis on the list they did not cite the IHDC report and the decision to treat cannabis with the same regulations as opium or cocaine passed with minimal media attention (Kendell 2008). Shortly thereafter a 1928 amendment to the Dangerous Drugs Act criminalized possession of cannabis, though still permitted doctors to prescribe it (Reuter & Stevens 2007). Finally in 1932, cannabis, extract of cannabis and cannabis tincture were removed from the British pharmacopoeia.

In the 1960s there was a re-emergence of research on the medical uses of cannabis in the UK, which coincided with drug liberation activists extolling the medical virtues of the plant (Taylor 2008).  Nevertheless, following the 1971 UN Convention on Psychotropic Substances the UK enacted the Misuse of Drugs Act, which scheduled and prohibited the regular medical use of cannabinol and its derivatives (including THC).  Cannabis itself was scheduled in 1973 with the introduction of the Misuse of Drugs Regulations, thereby prohibiting medical use of the plant altogether.  However a few cannabinoid pharmaceuticals are in limited use in the UK and other parts of the industrialized world.  Marinol, a synthetic THC product was licensed by the FDA in the United States for the treatment of nausea associated with chemotherapy in cancer patients.  However, its inconsistent delivery of active constituents and poor tolerability have prevented it from becoming widely used.  Nabilone, another synthetic cannabinoid with anti-emetic properties is licensed for use in the UK, but widespread marketing of this drug has been limited by its "Schedule II" classification in the US (Stott & Guy 2004).  

By the 1990s the medical cannabis movement in the UK had become more organized (if not widely known among the general public), led mainly by patients with multiple sclerosis (MS) who found relief in cannabis that no orthodox medicine could even come close to. In 1998 the Home Office licensed GW Pharmaceuticals to cultivate and supply cannabis for research purposes. The company began clinical trials on Sativex (an oralmucosal spray containing a variety of cannabinoids) in 2001 with MS and neuropathic pain patients (Taylor 2008).  This product is in the final stages of gaining regulatory approval and should be marketed in the UK soon. Cannabis based medicine extracts may offer significant advantages over single synthetic cannabinoids due to synergistic effects of minor cannabinoid and non-cannabinoid compounds (Stott & Guy 2004). However, it remains to be seen whether Sativex will be perceived as an improvement over orally administered cannabinoid pharmaceuticals, which are often considered inferior to smoked cannabis by people who self-medicate with it (Coomber et al. 2003). Grinspoon (1999) points out that smoking marijuana with others tends to increase sociability and openness, which can make it easier for some people to share difficult thoughts and feelings related to their state of health.  An unexpected outcome of nearly a century of cannabis prohibition is that self-medication traditions have had time to develop to the extent that pharmaceutical options may not be able to compete with them. 

Unfortunately, while the UK government is relatively open minded about the therapeutic use of cannabinoid pharmaceuticals, there are no current plans to make natural cannabis available to disabled persons, even though this is their preferred form and they will likely continue to use the illegal product (Coomber et al. 2003). This means that people who choose to medicate themselves with cannabis must either purchase their medicine illicitly or grow it themselves. Under current UK drug policy neither is a very desirable option. The quality and potency of cannabis appears to be quite variable throughout the UK with THC content of police seizures ranging from two to nearly 50% (Hardwick and King 2008). Anecdotal reports from students indicate that street dealers typically give very little information about the pedigree and/or quality of their products, leaving it up to the consumer to determine their potency and purity. Thus, it seems unlikely that most street dealers are interested in (or even capable of) providing a safe, consistent supply of medical grade marijuana. The quality control problem can be avoided by growing cannabis oneself (or by supporting the small grow operations of friends and neighbors) but this leaves one open to more serious charges of drug cultivation and intent to supply.

Skunk, Domestic Production and Self-Care in the UK
Part of the reluctance to re-classify/de-schedule cannabis so that it could once again be used for medicinal (or other) purposes relates to fears about “skunk.” The British cannabis market is reported to have undergone two major shifts in recent years. The first is the substitution of home grown cannabis for imported herbal cannabis and hashish. Second is a rise in the psychoactive strength of cannabis due to increased THC content, which is accompanied by a reduction in cannabidiol (CBD) in some varieties (Hardwick and King 2008; Potter et al. 2008).  British policy makers are preoccupied with the suspected link between such high potency, domestic cannabis (skunk) and psychiatric disorders in a minority of users (Acevedo 2007), which may be related to varieties with poor THC (an anxiety promoting compound) to CBD (an anxiety reducing compound) ratios (Potter et al. 2008).  However, there has not been a satisfactory investigation into what is driving the increased popularity/availability of highly potent, domestically produced “skunk” in the UK.  We also don’t know how the potency of cannabis influences consumption patterns, although participants in an American study were reported to alter their intake according to the strength of different grades of marijuana (Lenza 2007).

The cultivation process of high potency, skunk forms of cannabis involves culling male plants, which encourages female plants to produce more THC (and other cannabinoids) in their buds and flowers.  Over the past half century this method of growing cannabis has been adapted to indoor growing conditions, mainly by North American breeders.  However, the production of unfertilized female buds and flowers itself is nothing new and was known and used in India well before colonial times (Russo 2005).  In the North America (as in India), where medical marijuana research, use and policy are relatively well developed, this form of highly potent cannabis is prized for it’s medicinal properties (Melamede 2005).  Is it possible that in the UK increased availability of high potency cannabis reflects increased knowledge of and desire for medical marijuana?  

Most of the estimated two million (Coggans et al 2004) UK cannabis users avoid detection by the authorities and do not seek out treatment services.  Thus, they constitute a hidden population.  A growing proportion of this hidden population appear to be self-medicating an increasingly diverse range of health conditions (see Coomber et al. 2003; Taylor 2008; Ware et al. 2005). The (re)medicalization of cannabis in the UK must be considered within the context of a general revival of interest in herbal medicines (Taylor 2008), as complementary and alternative medicines increase in popularity (Ernst & White 2000).  The shift toward complementary and alternative medicines is in part explained by a growing dissatisfaction with mainstream medicine (Ernst 2000) and indeed this has been documented as a motivation for using cannabis therapeutically (Coomber et al. 2003).  The use of herbal medicines, including cannabis, may also be expanding due to the current social climate in which individuals are taking greater control of their own well-being by engaging in self-care (Jones 2006). The study of self-care is somewhat controversial (Kickbusch 1989) and could be used to justify blaming individuals for their own health problems or decreasing the level of professional health services provided by the state (Segall & Goldstein 1989; Ziguras 2004).  However, self-care practices increase the level of autonomy and sustainability in broader health care systems, which can result in better health outcomes (Waldstein 2010).  Again, self-medication with cannabis has been related to the ability to take control away from the health care system in order to become more self-sufficient (Coomber et al. 2003). 

Conclusion
Cannabis comes in variety of forms that are used for reasons ranging from recreational pleasure, to exploration of self and consciousness, to the enhancement of creativity to healing both mind and body.  Highly potent forms of cannabis appear to be particularly useful in treating many physical, psychological and spiritual health problems and could account for the increasing popularity of so-called skunk. As with any other herbal medicine, the use of cannabis by inexperienced and/or physiologically/psychologically vulnerable individuals can result in negative experiences (though from a pharmacological perspective cannabis is arguably among the least toxic drug/medicinal plants that humans consume).  Unfortunately, fear of skunk-induced mental health problems in a small minority of cannabis users drives prohibitionist policies that hinder the development and understanding of medicinal applications of cannabis.  Although international cannabis prohibition has been in place for nearly a century, most of our long history with this plant has involved its therapeutic use and the pleasure enhancing effects of cannabis seem almost inseparable from its healing capabilities.  We are living in time of political, social and economic uncertainty, which among other things threatens the stability of national healthcare systems.  Self-treatment with herbal remedies is a sustainable and often effective alternative to dependence on mainstream, professional medical care. The broad ranging effects of cannabis on the human body and mind, combined with its relatively easy cultivation, make it a truly holistic herbal medicine.  While important advances in cannabinoid pharmaceuticals are being made, we cannot discount the vibrant self-medication traditions that have grown up around this plant. 

Focusing on problematic use and the propagation of misinformation fuel cannabis prohibition in the UK, despite clear empirical evidence of safety and efficacy in a growing range of therapeutic applications. This puts people (often very ill people) at risk by forcing them to resort to an unpredictable supply and/or illegal production of their medicine. UK cannabis policy debates must move beyond its classification as a drug, toward the reconciliation of public safety with public wellbeing. In order to support innovative policies that protect the public from potential harms of cannabis, while also protecting the rights of people who choose to use cannabis as medicine we need to examine how people use cannabis to improve their lives. Research is needed, especially on the experiences of people who use cannabis to benefit, enrich and even prolong their lives.
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